Protalix: Clinical Trials

4 trials sponsored by Protalix, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 1 withdrawn. 4 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 34Completed 3, Withdrawn 1

Follow Protalix: new trials by email

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety, Efficacy, & PK of PRX-102 in Patients With Fabry Disease Administered Intravenously Every 4 Weeks
Pegunigalsidase alfa - Fabry Disease
Phase 3CompletedProtalix302017-07-102023-09-13
Study to Evaluate the Safety and EffIcacy of PRX-102 on Gastrointestinal Symptoms in Naïve Fabry Disease
PRX-102, Placebo - Fabry Disease
Phase 3WithdrawnProtalix2017-07-012018-01-08
Safety and Efficacy of PRX-102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa)
PRX-102 (pegunigalsidase alfa) - Fabry Disease
Phase 3CompletedProtalix222017-05-172023-09-13
Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function
PRX-102 (pegunigalsidase alfa), agalsidase beta - Fabry Disease
Phase 3CompletedProtalix782016-06-012023-09-13

Conditions studied

Fabry Disease (4)  ·  Abdominal Pain (1)  ·  Diarrhea (1)  ·  Proteinuria (1)

Interventions

agalsidase beta (1)

Countries

Czechia (3)  ·  Norway (3)  ·  United Kingdom (3)  ·  Italy (2)  ·  Netherlands (2)  ·  Slovenia (2)  ·  United States (2)  ·  Australia (1)  ·  Belgium (1)  ·  Canada (1)  ·  Denmark (1)  ·  Finland (1)  ·  France (1)  ·  Hungary (1)  ·  Spain (1)

Top investigators

Raul Chertkoff, MD (1)

Results publications

PMID 39847314, PMID 37865771, PMID 37940383